移至主內容

Featured review: Uterotonic agents for preventing postpartum haemorrhage

This news item is more than 6 years old.
Image

Which drug is best for reducing excessive blood loss after birth?

The aim of this Cochrane Review was to find out which drug is most effective in preventing excessive blood loss at childbirth and has the least side effects. The authors collected and analysed all the relevant studies to answer this question.

The review’s lead author Dr Ioannis Gallos from the University of Birmingham explains, “Bleeding after birth is the most common reason why mothers die in childbirth worldwide. Although most women will have moderate bleeding at birth, others may bleed excessively, and this can pose a serious risk to their health and life. To reduce excessive bleeding blood loss at childbirth, the routine administration of a drug to contract the uterus (uterotonic) has become standard practice across the world. The aim of this research was to identify which drug is most effective in preventing excessive bleeding after childbirth and has the least side-effects.

The different drugs oxytocin, misoprostol, ergometrine, carbetocin, and combinations of these drugs, each have different effectiveness and side-effects. Some of the side effects identified include: vomiting, high blood pressure and fever. We analysed all the available evidence to compare all of these drugs and calculated a ranking among them providing robust effectiveness and side-effect profiles for each drug.

The referenced media source is missing and needs to be re-embedded.

We found all drugs were generally effective for preventing excessive bleeding when compared with no uterotonic drug treatment. Ergometrine plus oxytocin combination, carbetocin, and misoprostol plus oxytocin combination may have some additional benefits compared with the current standard oxytocin. The two combination drugs, however, are associated with significant side effects that women might find disturbing compared with oxytocin. Carbetocin may have some additional benefits compared with oxytocin and appears to be without an increase in side effects.”

This updated review includes 196 studies involving 135,559 women. Studies were conducted across 53 countries. In most studies women were giving birth normally and in a hospital.

我們對Cookie的使用

我們使用必要的 cookie 使我們的網站正常運作。我們還希望設置可選擇分析的 cookie,以幫助我們進行改進網站。除非您啟用它們,否則我們不會設置可選擇的 cookie。使用此工具將在您的設備上設置 cookie,以記住您的偏好。您隨時可以隨時通過點擊每個頁面下方的「Cookies 設置」連結來更改 Cookie 偏好。
有關我們使用 cookie 的更多詳細資訊,請參閱我們的 cookie 頁面

接受所有
配置